Nurix Therapeutics, Inc. (NRIX) KPIs and segments
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
KPIs & segments
Operating metrics and segments that drive Nurix Therapeutics's business
Nurix Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
Nurix Therapeutics's fiscal year ends November 30 — Q3 FY26 = CQ3 2026 (calendar quarter).
| Add to chart | Metric | Q3 FY26 CQ3 2026 | Q2 FY26 CQ2 2026 | Q1 FY26 CQ1 2026 | Q4 FY25 CQ4 2025 | Q3 FY25 CQ3 2025 | Q2 FY25 CQ2 2025 | Q1 FY25 CQ1 2025 | Q4 FY24 CQ4 2024 | Q3 FY24 CQ3 2024 | Q2 FY24 CQ2 2024 | Q4 FY23 CQ4 2023 | Q3 FY23 CQ3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
License revenue($M) | 653 | 0 | 0 | 0 | 30 | 0 | 0 | 0 | 0 | 0 | |||
Collaboration revenue($M) | 19.9 | 9.04 | 6.25 | 13.6 | 7.89 | 14.1 | 18.5 | 13.3 | 12.6 | 12.1 | 15.2 | 18.5 | |
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-10-13.
See a number that looks wrong?